Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 02, 2021 09:00 ET | Source: uniQure Inc.

uniQure Announces Presentations at Upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, July 02, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
June 22, 2021 11:31 ET | Source: uniQure Inc.

uniQure Announces Positive 52-Week Clinical Data from HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B and Provides Regulatory Update

~ Sustained increases in Factor IX (FIX) levels with mean FIX activity of 41.5 percent of normal in full study population one year following a single administration of etranacogene dezaparvovec ~ ~...
June 22, 2021 11:31 ET | Source: uniQure Inc.

uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)

~ Expands uniQure’s Pipeline of Innovative Gene Therapies to Treat Neurological Disorders ~ ~ Strengthens uniQure’s Global Leadership in the Development of Gene Therapies that Employ miRNA Silencing...
June 16, 2021 07:05 ET | Source: uniQure Inc.

uniQure Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, June 16, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
June 02, 2021 10:31 ET | Source: uniQure Inc.

UPDATE -- uniQure to Participate in Multiple Upcoming Industry Conferences in June

LEXINGTON, Mass. and AMSTERDAM, June 02, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
June 02, 2021 07:34 ET | Source: uniQure Inc.

uniQure to Participate in Multiple Upcoming Industry Conferences in June

LEXINGTON, Mass. and AMSTERDAM, June 02, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
May 27, 2021 07:05 ET | Source: uniQure Inc.

uniQure Announces Positive Recommendation to Advance Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 27, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
May 13, 2021 07:00 ET | Source: uniQure Inc.

uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to AAV5 Vector

~ Data Show No Clinically Significant Correlation Between Pre-Existing NAbs and FIX Activity ~ ~ Further Supports Potential for AAV5 Gene Therapies to be Viable Treatments in Nearly All Patients -- ...
May 10, 2021 07:05 ET | Source: uniQure Inc.

uniQure Announces First Quarter 2021 Financial Results and Highlights Recent Company Progress

~ 52-week follow-up data from HOPE-B pivotal study expected to be presented later this quarter ~ ~ Announced closing of the global commercialization and license agreement with CSL Behring for...
May 06, 2021 07:00 ET | Source: uniQure Inc.

uniQure announces closing of commercialization and license agreement with CSL Behring

LEXINGTON, Mass. and AMSTERDAM, May 06, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right